


EXPRESS MAIL CERTIFICATE

Date July 3, 2001 Label No. EL920080271US

I hereby certify that, on the date indicated above I deposited this paper or fee with the U.S. Postal Service & that it was addressed for delivery to the Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

MICHELE
WATSON
Name (Print)


Signature

File No. 242/9-1568

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Roberto VALDUCCI

Serial No.: To Be Assigned

Filed : Herewith - July 3, 2001

For : ORAL SOLID PHARMACEUTICAL FORMULATIONS WITH pH DEPENDANT
MULTIPHASIC RELEASE

Commissioner for Patents
Washington, DC 20231

PRELIMINARY AMENDMENT

Sir:

Prior to the examination of the above-referenced application, please amend the above-identified application as follows. A clean copy of the claims as amended is enclosed.

IN THE CLAIMS

In Claim 6, line 1, delete "any of the preceeding claims", insert --claim 1--.

In Claim 10, line 1, change "claims 1 or 2 or 3 or 4 or 5 or 6" to --claim 1--.

In Claim 13, line 1, change "claims 1 or 2 or 3" to -- claim 1--.

In Claims 15, 18 and 19, line 1, change "any preceeding claims 1-9" to --claim 1--.

REMARKS

Favorable consideration and entry of the application is respectfully requested. The multiple dependency of claims 6, 10, 13, 15, 18 and 19 have been removed to reduce the filing fee.

Respectfully submitted,



William J. Sapone
Registration No. 32,518
Attorney for Applicant(s)

COLEMAN SUDOL SAPONE P.C.
708 Third Avenue
New York, NY 10017
Phone: (212) 679-0090
Fax: (212) 679-9121
WJS/bc
(#appl00)

708 Third Avenue
New York, NY 10017
Phone: (212) 679-0090
Fax: (212) 679-9121
WJS/bc
(#appl00)

AMENDED CLAIMS

- 1) Oral solid formulation containing, as active ingredient, a substance useful in the Inflammatory Bowel Disease therapy, characterized by the association of different polymers or mixtures of polymers, each one soluble starting from a pH value different from the others and ranging from 6 to 7, and by the multiphasic release of such active ingredient, each phase occurring at a different pH value ranging from 6 to 7.
- 2) Formulation according to claim 1 wherein such association of polymers or mixtures of polymers includes a polymer or mixture of polymers soluble starting from pH 6, a polymer or mixture of polymers soluble starting from pH 6.5, and a polymer or mixture of polymers soluble starting from pH 7.
- 3) Formulation according to claim 2 wherein the release of the active ingredient in every phase occurs in the following pH-dependent ratios:

pH = 6	⇒	10-60%	of the active ingredient, preferably 30-35%
pH = 6.5	⇒	10-60%	of the active ingredient, preferably 30-35%
pH = 7	⇒	10-60%	of the active ingredient, preferably 30-35%
- 4) Formulation according to claim 1 wherein such active ingredient is mesalazine.
- 5) Formulation according to claim 1 wherein such active ingredient is chosen from the group including steroids, antibiotics and anti-inflammatories.
- 6) Formulation according to claim 1 in the form of micro-tablets, tablets, granules or microgranules or pellets of three types, each one presenting a coating including a polymer soluble starting from a pH value ranging from 6 to 7, such pH value being different for each of such three types.

- 7) Formulation according to claims 6 wherein such coating contains also from 0 to 40% of a fatty acid at 12-20 carbon atoms and from 0 to 40% of a pharmaceutically acceptable plasticizer.
- 8) Formulation according to claim 6 wherein the tablets, micro-tablets, granules or microgranules or pellets are dosed in capsules.
- 9) Formulation according to claim 6 wherein the granules or microgranules or pellets are dosed in sachets or dispensers for granules.
- 10) Formulation according to claim 1 in the form of a multilayer tablet.
- 11) Formulation according to claim 10 wherein the multilayer tablet is made of three layers, each one including, besides the active ingredient and the excipients commonly utilized for the preparation of tablets, a polymer or a mixture of polymers soluble starting from a pH value ranging from 6 to 7 and different from the one at which the polymer or mixture of polymers dissolve in the other two layers.
- 12) Formulation according to claim 11 wherein the internal layer includes a polymer or mixture of polymers soluble starting from pH 7, one of the external layers includes a polymer or mixture of polymers soluble starting from pH 6.5 and the second external layer includes a polymer or a mixture of polymers soluble starting from pH 6.
- 13) Formulation according to claim 1 in the form of tablets or multilayer tablets including, also in the tablet core from 5 to 35% of the polymer or mixture of polymers utilized in their coating, from 0 to 10% of a fatty acid at 12- 20 carbon atoms and from 0 to 10% of a pharmaceutically acceptable plasticizer.
- 14) Formulation according to claim 13 wherein the multilayer tablets have a coating including a polymer or mixture of polymers soluble at pH 6.

